Real-World Therapeutic Outcomes of S-1 Adjuvant Chemotherapy for pStage II/III Gastric Cancer in the Elderly

Abstract

<b><i>Background:</i></b> The predictive factors for discontinuation of S-1 administration and prognostic factors in elderly patients with pStage II/III gastric cancer receiving S-1 adjuvant chemotherapy remain unclear. <b><i>Methods:</i></b> Between January 2004 and December 2016, 80 elderly gastric cancer patients (≥70 years) undergoing curative D2 gastrectomy were enrolled in this study. Predictive factors for completion of S-1 administration over 1 year, adverse events due to S-1 administration, and prognostic factors for overall survival (OS) and relapse-free survival (RFS) were evaluated. <b><i>Results:</i></b> Twenty-eight patients (35%) completed 8 courses of S-1. The median relative dose intensity was 82.1% (IQR 31.1–100%). The incidence rates of hematological and nonhematological adverse events were acceptable. Distal gastrectomy was an independent predictive factor for completion of S-1 administration (odds ratio [OR] 0.364; 95% confidence interval [CI] 0.141–0.939; <i>p</i> = 0.037). Higher postoperative neutrophil count/lymphocyte count (N/L) ratio and more advanced stage adversely influenced OS. Multivariate analysis revealed that a higher postoperative N/L ratio and more advanced stage adversely affected RFS. <b><i>Conclusion:</i></b> To complete adjuvant S-1 administration to elderly patients with pStage II/III gastric cancer, total gastrectomy should be avoided if possible. A new regimen for elderly gastric cancer patients with higher postoperative N/L ratios and more advanced stage should be established.

Favorable efficacy of S‐1 treatment for locoregionally advanced cutaneous squamous cell carcinoma in the head and neck region

“…Most systemic therapies, including anti–PD‐1 monotherapies, for advanced head and neck CSCC require intravenous administration. S‐1 (comprising tegafur, gimeracil, and oteracil potassium) is an oral drug with a low incidence of severe adverse events (AEs) 18 that is approved for the treatment of gastric, colon, rectal, nonsmall cell lung, pancreatic, biliary tract, breast, and head and neck cancers. Given its approval for head and neck cancer, this agent may be reimbursed for head and neck CSCC in Japan.…”

Long-Term Survival Outcomes of Elderly Patients Treated With S-1 or Capecitabine Plus Oxaliplatin for Stage II or III Gastric Cancer: A Multicenter Cohort Study

“…In the CLASSIC study, patients treated with CAPOX had significantly better RFS and similar OS compared with patients treated with surgery alone [ 9 10 ]. Evidence of the efficacy of AC for elderly patients is limited [ 9 11 12 ]. Thus, most clinicians have difficulty developing AC treatment plans for elderly patients because they have a higher incidence of comorbidities, greater risk of adverse events, and shorter life expectancies [ 13 ].…”